mercaptopurine

(redirected from 6-MP)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for mercaptopurine

a drug (trade name Purinethol) that interferes with the metabolism of purine and is used to treat acute lymphocytic leukemia

References in periodicals archive ?
Finally, an in vitro study (10) suggested an alternative biochemical mechanism: XO inhibition by allopurinol may lead to preferential 6-MP oxidation via aldehyde oxidase, with the production of dihydroxy-6-MP, a compound responsible for feedback inhibition of TPMT activity.
A 53-year-old woman with Crohn disease receiving 6-MP monotherapy underwent liver biopsy for investigation of elevated aminotransferases.
But when the women on azathioprine or 6-MP were compared with women with IBD who were not on one of the purines, there was no increased risk in malformation - which indicates that it is not prenatal exposure to azathioprine or 6-MP but the condition itself that may increase the risk of malformations to some extent.
Limitations to the present study include the lack of standardized dosing of AZA or 6-MP and the lack of clinical correlation.
Measuring 6-TGN also can provide reassurance to physicians who are reluctant to prescribe the full standard doses of azathioprine and 6-MP.
4] Nonstandard abbreviations: 6-MP, 6-mercaptopurine; 6-TIMP, 6-thioinosine monophosphate; 6-TG, 6-thioguanine; 6-TGN, 6-thioguanine nucleotide; 6-MMP, 6-methylmercaptopurine; 6-MMPN, 6-methylmercaptopurine nucleotide; TPMT, thiopurine methyltransferase; 6-TGTP, 6-thioguanosine triphosphate; LC/MS/MS, liquid chromatography-tandem mass spectrometry; DTT, dithiothreitol; 6-TGMP, 6-thioguanosine monophosphate; 6-TGDP, 6-thioguanosine diphosphate; Me6-TIMP, methyl 6-thioinosine monophosphate; Me6-TIDP, methyl 6-thioinosine diphosphate; Me6-TfrP, methyl-6thioinosine triphosphate; 8-BA, 8-bromoadenine; UV, ultraviolet; and RFLP, restriction fragment length polymorphism.
3]H-labeled methyl group in S-adenosyl-methionine to 6-MP over 1 h at 37[degrees]C was followed by [beta]-scintillation counting after extraction of the product (6-methyl-MP).
In March 2006, REMICADE became the first biologic therapy approved to treat moderately to severely active UC in the European Union (EU), in patients with an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or those intolerant to or contraindicated for such therapies.
Then, high 6-TGN concentrations in RBCs could be correlated with low erythrocyte TPMT activity, which exhibits a favorable clinical outcome in children with acute lymphoblastic leukemia treated by 6-MP [4].
6-MP is activated intracellularly by the conversion of 6-MP into thio-IMP (tIMP) by the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase [3, 4].
GETAID, the Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif study, which translates into English as "Group Therapeutic Study of the Inflammatory Affections of the Digestive Tract," an investigator-initiated, randomized, multicenter, placebo-controlled study evaluated the combination of Azathioprine or 6-mercaptopurine (AZA or 6-MP) in combination with infliximab as an induction regimen (3 infusions at 0, 2 and 6 weeks), compared with AZA or 6-MP alone in patients with steroid-dependent CD.
6-MP is further converted in the liver and gut to 6-thioguanine nucleotides, the pharmacologically active metabolites, by several enzymes, including hypoxanthine guanine phosphoribosyltransferase.
In February 2006, REMICADE was approved in the EU for the treatment of moderately to severely active ulcerative colitis (UC) in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
The expanded indication would include treatment of moderately to severely active ulcerative colitis (UC) in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
and Schering-Plough Corporation today announced the European Commission has granted approval of REMICADE(R) (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in patients who have had an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.